JP2015509705A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509705A5
JP2015509705A5 JP2014551570A JP2014551570A JP2015509705A5 JP 2015509705 A5 JP2015509705 A5 JP 2015509705A5 JP 2014551570 A JP2014551570 A JP 2014551570A JP 2014551570 A JP2014551570 A JP 2014551570A JP 2015509705 A5 JP2015509705 A5 JP 2015509705A5
Authority
JP
Japan
Prior art keywords
absent
seq
nucleic acid
acid molecule
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014551570A
Other languages
English (en)
Japanese (ja)
Other versions
JP6415327B2 (ja
JP2015509705A (ja
Filing date
Publication date
Priority claimed from PCT/EP2012/000089 external-priority patent/WO2012095303A1/en
Application filed filed Critical
Priority claimed from PCT/EP2013/000056 external-priority patent/WO2013104540A1/en
Publication of JP2015509705A publication Critical patent/JP2015509705A/ja
Publication of JP2015509705A5 publication Critical patent/JP2015509705A5/ja
Application granted granted Critical
Publication of JP6415327B2 publication Critical patent/JP6415327B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014551570A 2012-01-10 2013-01-10 新規なc5a結合性核酸 Active JP6415327B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP12000106 2012-01-10
EP12000106.0 2012-01-10
EPPCT/EP2012/000089 2012-01-10
PCT/EP2012/000089 WO2012095303A1 (en) 2011-01-10 2012-01-10 Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
EP12006960 2012-10-08
EP12006960.4 2012-10-08
PCT/EP2013/000056 WO2013104540A1 (en) 2012-01-10 2013-01-10 New c5a binding nucleic acids

Publications (3)

Publication Number Publication Date
JP2015509705A JP2015509705A (ja) 2015-04-02
JP2015509705A5 true JP2015509705A5 (enExample) 2016-03-03
JP6415327B2 JP6415327B2 (ja) 2018-10-31

Family

ID=48781063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014551570A Active JP6415327B2 (ja) 2012-01-10 2013-01-10 新規なc5a結合性核酸

Country Status (18)

Country Link
US (5) US9518265B2 (enExample)
EP (1) EP2802660B1 (enExample)
JP (1) JP6415327B2 (enExample)
KR (1) KR102034203B1 (enExample)
CN (1) CN104145018B (enExample)
AU (2) AU2013209131A1 (enExample)
BR (1) BR112014016877B1 (enExample)
CA (1) CA2860806C (enExample)
DK (1) DK2802660T3 (enExample)
ES (1) ES2786007T3 (enExample)
IL (1) IL233516B (enExample)
IN (1) IN2014DN05665A (enExample)
MX (1) MX362061B (enExample)
PL (1) PL2802660T3 (enExample)
PT (1) PT2802660T (enExample)
RU (1) RU2645261C2 (enExample)
SG (2) SG11201403771SA (enExample)
WO (1) WO2013104540A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105849323A (zh) 2013-10-28 2016-08-10 多茨设备公司 过敏原检测
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
US11172873B2 (en) 2018-05-17 2021-11-16 The Procter & Gamble Company Systems and methods for hair analysis
MX2020012225A (es) 2018-05-17 2021-01-29 Procter & Gamble Sistemas y metodos para el analisis de la cobertura del cabello.
EP3586865A1 (en) * 2018-06-21 2020-01-01 Charité - Universitätsmedizin Berlin Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
US11384357B2 (en) 2018-06-29 2022-07-12 The Procter And Gamble Company Aptamers for personal care applications
AU2019378732A1 (en) * 2018-11-12 2021-05-27 Aptarion Biotech Ag CXCL8 binding nucleic acids
WO2020214784A1 (en) 2019-04-16 2020-10-22 The Procter & Gamble Company Aptamers for odor control applications
US12039732B2 (en) 2021-04-14 2024-07-16 The Procter & Gamble Company Digital imaging and learning systems and methods for analyzing pixel data of a scalp region of a users scalp to generate one or more user-specific scalp classifications
CN113150106B (zh) * 2021-04-26 2022-08-16 华中农业大学 来源于补体成分C5a的抗菌肽及其应用
EP4620474A1 (en) 2024-03-20 2025-09-24 APTARION biotech AG Method of treating a disorder with a c5a inhibitor
WO2025196240A1 (en) 2024-03-20 2025-09-25 Aptarion Biotech Ag Method of treating a disorder with a c5a inhibitor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6140490A (en) 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6652886B2 (en) 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
ATE469164T1 (de) 2001-10-26 2010-06-15 Noxxon Pharma Ag Modifizierte l-nukleinsäure
ATE441706T1 (de) 2002-02-20 2009-09-15 Gen Hospital Corp Konjugate mit biologisch abbaubarem polymer und verwendung dafür
RU2394041C2 (ru) 2003-04-13 2010-07-10 Энзон Фармасьютикалз, Инк. Полимерные олигонуклеотидные пролекарства
GB0314472D0 (en) 2003-06-20 2003-07-23 Warwick Effect Polymers Ltd Polymer
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
EP1713509A2 (de) 2004-02-09 2006-10-25 Noxxon Pharma AG Verfahren zur herstellung von konjugaten aus polysacchariden und polynukleotiden
DK3385384T3 (da) * 2004-02-12 2020-06-29 Archemix Llc Aptamer-lægemidler nyttige ved behandlingen af komplement-relaterede lidelser
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
CA2940803A1 (en) 2004-03-23 2005-10-27 Ascendis Pharma Gmbh Prodrug linker
WO2006052790A2 (en) 2004-11-05 2006-05-18 The Children's Hospital Of Philadelphia Biodegradable linkers for molecular therapies
JP2008526915A (ja) * 2005-01-17 2008-07-24 イエリニ・アクチェンゲゼルシャフト C5a受容体アンタゴニスト
PT1991275E (pt) 2006-03-08 2015-02-03 Archemix Llc Aptâmeros de ligação ao complemento e agentes anti-c5 úteis no tratamento de distúrbios oculares
AU2007296054B2 (en) 2006-09-15 2013-03-28 Enzon Pharmaceuticals, Inc. Hindered ester-based biodegradable linkers for oligonucleotide delivery
US20100062436A1 (en) 2006-10-31 2010-03-11 Noxxon Pharma Ag Methods for Detection of a Single- or Double-Stranded Nucleic Acid Molecule
CN101809154A (zh) * 2007-09-24 2010-08-18 诺松制药股份公司 C5a结合核酸
CN102421350B (zh) 2009-03-11 2014-12-17 奥林巴斯医疗株式会社 图像处理系统、其外部装置及其图像处理方法
US20120065254A1 (en) 2009-03-23 2012-03-15 Noxxon Pharma Ag C5A binding nucleic acids and the use thereof
EP2561079A1 (en) 2010-04-21 2013-02-27 Noxxon Pharma AG Lipid binding nucleic acids
CA2824073A1 (en) * 2011-01-10 2012-07-19 Noxxon Pharma Ag Nucleic acid molecule having binding affinity to a target molecule and a method for generating the same
AU2012325233A1 (en) 2011-10-21 2014-04-24 Noxxon Pharma Ag Glucagon binding nucleic acids
MX2014008456A (es) 2012-01-10 2014-11-25 Noxxon Pharma Ag Acidos nucleicos que enlazan especificamente a cgrp.

Similar Documents

Publication Publication Date Title
JP2015509705A5 (enExample)
RU2014132708A (ru) НОВЫЕ СВЯЗЫВАЮЩИЕ C5a НУКЛЕИНОВЫЕ КИСЛОТЫ
Zeisberg et al. Cellular mechanisms of tissue fibrosis. 1. Common and organ-specific mechanisms associated with tissue fibrosis
JP2022017333A5 (enExample)
RU2010116245A (ru) НУКЛЕИНОВЫЕ КИСЛОТЫ, СВЯЗЫВАЮЩИЕ C5a
US11904057B2 (en) Nanoparticle-hydrogel composite for nucleic acid molecule delivery
AU2012257774B2 (en) High-affinity, dimeric inhibitors of PSD-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
JP2013524792A5 (enExample)
JP2006513724A5 (enExample)
US20080305073A1 (en) Therapeutic Agents for the Treatment of Hmgb1-Related Pathologies
JP2010539893A5 (enExample)
JP2012525124A5 (enExample)
JP2008504335A5 (enExample)
CN104450691A (zh) 结合海帕西啶的核酸
CN109843378A (zh) 用于治疗肺血管疾病的组合物和方法
CN103502262A (zh) 基于双头两亲性肽的自组装水凝胶
JP2014533098A5 (enExample)
CN103012562A (zh) 一种双重靶向的d构型多肽及其递药系统
RU2014132706A (ru) Нуклеиновые кислоты, специфически связывающие cgrp
JP2021073179A (ja) アポトーシスを誘導するための組成物及び方法
CN106868009A (zh) 一种用于检测妇科慢性盆腔炎的试剂盒及其检测方法
WO2019096095A1 (zh) 整合素受体靶向的抗癌偶联物
JP2011155913A (ja) TNF−αに結合するアプタマー分子
WO2011140365A1 (en) Targeted particles comprising landscape phage fusion proteins and heterologous nucleic acid
JP2020513192A (ja) 低分子rna、並びに線維増殖性疾患及び/又は症候群の予防及び/又は治療におけるその応用